|
Match
|
Document |
Document Title |
|
|
7615544 |
Method of improving cumulative embryo score and quantity of fertilized oocytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone
A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and...
|
|
|
7572780 |
Method and kit for reducing the symptoms of peripheral vascular disease
A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral...
|
|
|
7521438 |
Combination of loteprednol and β2-adrenoceptor agonists
The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one β 2 adrenoceptor agonist for the simultaneous, sequential or separate treatment of...
|
|
|
7482334 |
Therapeutic treatment methods
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include...
|
|
|
7462646 |
Osteoclastogenesis inhibitors and uses thereof
The present invention provides a method of reducing or inhibiting osteoclast development induced by the receptor for activation of nuclear factor kappa B ligand (RANKL), comprising the step of...
|
|
|
7456160 |
Formulation
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound...
|
|
|
7429576 |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded...
|
|
|
7419971 |
Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17α-alkoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate type...
|
|
|
7402577 |
Androstane 17-beta-carboxamides as androgen receptor modulators
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as...
|
|
|
7371741 |
Estradiol derivatives and pharmaceutical compositions using same
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula:
wherein the variables are defined in the...
|
|
|
7351699 |
Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent
The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation...
|
|
|
7300669 |
Fluticasone lotion having improved vasoconstrictor activity
A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and...
|
|
|
7253155 |
Combinations for the treatment of immunoinflammatory disorders
The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid...
|
|
|
7223387 |
Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to...
|
|
|
7205287 |
Platinum complexes having antitumor activity
A platinum complex having antitumor activity in which the metal ligands are dehydrocholic acid and phosphine.
|
|
|
7199116 |
Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
Modulating the metabolism of a dieting mammal by administering to the dieting mammal the metabolic modulating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone.
|
|
|
7199115 |
17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
New 17α-fluorosteroid compounds of formula (I) are disclosed:
wherein R 1 denotes H or methyl; R 2 and R 3 each denote H, Cl or methyl; and either a double bond or a single bond is present...
|
|
|
7186401 |
Dry powder for inhalation
The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a...
|
|
|
7182960 |
Pharmaceutical compositions for nasal delivery of oestradiol and norethisterone
The present invention relates to a pharmaceutical composition for administration by the nasal route of 17-β-oestradiol and norethisterone.
|
|
|
7182956 |
Stable topical drug delivery compositions
A stable composition of a drug comprising a carrier having a phosphatidylcholine component which entraps the drug is applied to the skin for transdermal delivery of the drug.
|
|
|
7169768 |
Method of decreasing atherosclerosis and its complications
A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease wherein the method involves administering to...
|
|
|
7064116 |
GABAA modulating neurosteroids
The present invention relates to novel steroid derivatives that ace on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex as well as methods for making the same and their...
|
|
|
7060694 |
High potency dihydroergotamine compositions
The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using...
|
|
|
7053077 |
Use of biogenic estrogen sulfamates for hormone replacement therapy
The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in...
|
|
|
7045513 |
DHEA composition and method
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation...
|
|
|
7037907 |
Estradiol conjugates and uses thereof
A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.
|
|
|
7018991 |
17β-amino and hydroxylamino-11 β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
|
|
6977250 |
Prevention of ovarian cancer by administration of progestin products
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as...
|
|
|
6969708 |
Process for the preparation of a high purity composition comprising (7α, 17α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn-5(10)-en-20-yn-3-one
The invention pertains to a process for the preparation of a high purity composition of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-o
ne. The process provides for a composition...
|
|
|
6949531 |
14 β, 16, 17-methylene steroids as novel androgens
Disclosed are androgenic steroids of the (14β,17α)-17-(hydroxymethyl) type. The invention relates to an improvement thereof, which is based on the presence of a β-oriented, annellated...
|
|
|
6924274 |
Use of Δ5-androstene-3β-ol-7,17-dione in the treatment of lupus erythematosus
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which...
|
|
|
6906049 |
Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
The present invention relates to the field of chemistry and more particularly to that of therapeutic chemistry. The invention relates more particularly to novel contraceptive compositions formed...
|
|
|
6900239 |
Tumor chemopotentiation using isocoumarin derivatives
A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation...
|
|
|
6900193 |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
The present invention relates, inter alia, to compounds having the general formula:
in which: R 1 is a member selected from the group consisting of —OCH 3 , —SCH 3 , —N(CH 3 ) 2 ,...
|
|
|
6881728 |
14-β, 17-α-hydroxymethylandrostane derivatives as androgens
Androgenic steroids having a (14β,17α-)-17-(hydroxymetheyl) configuration, useful for the preparation of male contraceptives and pharmaceutical formulations for the treatment of androgen...
|
|
|
6878699 |
Taccalonolide microtubule stabilizing agents
In accordance with the present invention, there have been identified extracts from a tropical plant that initiate paclitaxel-like microtubule bundling. Bioassay-directed purification yields the...
|
|
|
6852710 |
2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
The application discloses novel 2-alkoxyestradiol analogs which exhibit anti-proliferative properties, and methods of making and using such compounds to inhibit undesired cell proliferation and...
|
|
|
6844320 |
Treatment of preeclampsia, toxemia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both,...
|
|
|
6831073 |
Hormonal composition consisting of an oestrogen compound and of a progestational compound
A method of treating estrogenic deficiencies in women while further avoiding the appearance of osteoporosis, withdrawal bleeding and cardiovascular diseases in post-menopausal women without any...
|
|
|
6803060 |
Composition to boost libido
There is provided a natural composition for boosting the libido of an individual, the composition including an effective amount of an aphrodisiac and a compound to increase blood flow to the pelvic...
|
|
|
6777389 |
Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides
The present invention is directed to a composition and method for enhancing the appearance of skin or tissue. The invention is preferably a combination of elastin-derived peptides and steroidal...
|
|
|
6767903 |
New7α, 17α-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
The invention relates to new 7α, 17α, 17β-substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent...
|
|
|
6765002 |
Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of increasing TGF-β expression...
|
|
|
6759400 |
Meiosis regulating compounds
Certain compounds, structurally related to natural compounds which can be extracted i.a. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in...
|
|
|
6737417 |
Compounds with hydroxycarbonyl-halogenoalkyl side chain
The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral...
|
|
|
6706700 |
14β,15β-methylene-17α-hydroxymethyl-androgens
The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14β,15β-cyclopropane ring and a 17α hydroxymethyl group. These steroids according to the...
|
|
|
6696432 |
Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
The present invention concerns the combination of dehydroepiandrosterone (DHEA) and at least one aromatase inhibitor and the use of such a combination to produce a medicament for treating relative...
|
|
|
6683071 |
Initiation of oestrus
This invention relates to a method for the initiation of oestrus and ovulation early postpartum, especially but not exclusively, in dairy cows which comprises supplying a prostaglandin post partum...
|
|
|
6676934 |
Pharmaceutical composition with tumor necrosis factor A and 2-methoxyestrone-3-0-sulphamate for inhibition of estrone sulphatase
A composition is described. The composition comprises i) a compound comprising a sulphamate group (“a sulphamate compound”); and ii) a biological response modifier.
|
|
|
6670350 |
Method of administering dienogest in high dosages to reduce the body of the breast and pharmaceutical composition for same
A method of administering dienogest to a women in high dosages for reducing the body of the breast is described. The dosage should be at least ten times the effective dosage for inhibiting...
|